Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06733922 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Study acronym: ELIOS
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion pushed from Nov 30, 2027 to Nov 30, 2028v8
  2. Study sites: 11 to 14
    • Primary completion date: Nov 22, 2027 to Nov 30, 2027
    v7
  3. Study sites: 9 to 11v6
  4. Study sites: 5 to 9v5
  5. Study sites: 4 to 5v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 2 to 4v3
  2. Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Multiple Sclerosis
1,011 trials monitored
See 34 trials at risk
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.
Trial Details
NCT Number NCT06733922
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Relapsing Remitting Multiple Sclerosis (RRMS)
Related terms Charcot-Marie-Tooth disease, Type 1F, Multiple Sclerosis, Relapsing-Remitting
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov